Kisspeptin-10
Kisspeptin-10 is a synthetic decapeptide that activates the KISS1R (GPR54) receptor to modulate GnRH neuron signaling. It is researched for applications in neuroendocrine regulation, metabolic signaling, oncology, and cardiovascular biology.
Kisspeptin-10 is a synthetic decapeptide fragment of the kisspeptin family that activates the KISS1R (GPR54) receptor. It is widely used in laboratory research to study downstream signaling cascades involving intracellular calcium mobilization, kinase activation, and transcriptional responses relevant to neuroendocrine regulation, metabolic sensing, and cell migration phenotypes.
Overview
Kisspeptin-10 is the shortest bioactive fragment of the kisspeptin family, retaining full agonist activity at the KISS1R receptor. It serves as a critical experimental tool for studying the hypothalamic-pituitary-gonadal (HPG) axis, particularly in understanding how GnRH neurons are activated and how pulsatile gonadotropin release is regulated. Beyond reproductive neuroendocrinology, kisspeptin signaling has been implicated in metabolic regulation, tumor metastasis suppression, and cardiovascular biology.
Mechanism of Action
Kisspeptin-10 binds and activates the KISS1R (GPR54) receptor, a Gq/11-coupled GPCR. Receptor activation triggers phospholipase C-mediated hydrolysis of PIP2, generating IP3 and DAG, which leads to intracellular calcium mobilization and protein kinase C activation. In GnRH neurons, this signaling cascade increases neuronal excitability and drives pulsatile GnRH secretion, which in turn regulates LH and FSH release from the anterior pituitary. The system serves as a gatekeeper for puberty onset and ongoing reproductive function.
Reconstitution Calculator
Kisspeptin-10
**Kisspeptin-10** is a synthetic decapeptide fragment of the kisspeptin family t
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Energy Balance and Metabolic Interfaces
Kisspeptin neurons are widely studied as integrators of metabolic state signals with neuroendocrine outputs. Preclinical genetics and receptor-localization studies have reported Kiss1r expression in adipose tissues and have used receptor loss-of-function approaches to evaluate changes in adiposity-related phenotypes and energy expenditure endpoints in animal models Tolson et al. (2014). These findings support ongoing research into how KISS1R signaling intersects with metabolic pathways and peripheral tissue signaling.
Oncology and Metastasis Suppression
KISS1/kisspeptin signaling has been investigated in oncology research primarily for its association with metastatic behavior and cell motility phenotypes. Published work has reported kisspeptin-linked modulation of tumor cell migration and adhesion/invasion processes across multiple tumor contexts Lee et al. (2005), Kotani et al. (2001). Additional reports discuss potential coupling between kisspeptin signaling, circadian/light-cycle variables, and melatonin pathway markers in mouse-based experimental designs evaluating tumor growth endpoints Cho et al. (2009).
Learning and Memory
Select studies have evaluated kisspeptin-related peptide analogs in rodent behavioral paradigms measuring spatial learning, navigation, and cognitive flexibility. Such work probes neuromodulatory signaling hypotheses and maps peptide-receptor activity onto circuit-level function in nonclinical models Arai et al. (2009).
Neural Circuit Processing
Research has examined kisspeptin-associated modulation of limbic and reward-circuit activity using experimental brain processing readouts, supporting broader investigation into how neuroendocrine peptides interface with motivational circuitry and affective processing Comninos et al. (2017).
Kidney and Cardiovascular Biology
Kisspeptin and KISS1R expression has been reported in renal tissue, and receptor-deficient mouse models have been used to study developmental and functional endpoints relevant to renal biology. In cardiovascular research, kisspeptin signaling has been evaluated for context-specific effects in vascular beds, including vasoreactivity and vascular signaling pathways, with emphasis on mechanistic interpretation and tissue-specific receptor biology Mead et al. (2007).
GnRH Neuron Activation and Gonadotropin Dynamics
Experimental work with kisspeptin ligands has characterized KISS1R-dependent activation of GnRH neuron signaling and associated changes in downstream gonadotropin secretion dynamics. These models are frequently used to examine pulse generation, receptor desensitization, and HPG axis response characteristics under defined stimulation paradigms Seminara et al. (2003), de Roux et al. (2003).
Safety Profile
Kisspeptin-10 has been administered intravenously in multiple clinical research studies with a favorable safety profile. In healthy volunteers and patient populations, reported side effects are minimal and transient, including mild facial flushing and a sensation of warmth. Due to its very short half-life (~28 minutes), effects are rapidly reversible. Continuous or high-dose administration can lead to KISS1R desensitization and paradoxical suppression of gonadotropin release, which is being explored as a potential therapeutic strategy for hormone-sensitive conditions. No serious adverse events have been reported in published clinical research studies.
Healthy Volunteer Gonadotropin Stimulation Studies
Dhillo et al. (2005) administered kisspeptin-54 (the full-length form) intravenously at 0.1-1.0 nmol/kg to healthy male volunteers (n=6), demonstrating robust LH and FSH release within 30-60 minutes. Building on this, Jayasena et al. (2011) administered kisspeptin-10 as an intravenous bolus (0.3-13.6 nmol/kg) and continuous infusion (0.1-1.28 nmol/kg/h) in healthy men, showing dose-dependent LH increases peaking at 45 minutes post-bolus. The shorter kisspeptin-10 form required approximately 10-fold higher molar doses than kisspeptin-54 for equivalent gonadotropin stimulation due to its shorter half-life.
IVF Oocyte Maturation Trigger
Abbara et al. (2015) conducted a proof-of-concept study using kisspeptin-54 (9.6 nmol/kg SC) as an alternative to hCG for triggering oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during IVF (n=53). The kisspeptin trigger produced adequate oocyte maturation rates (71% mature oocytes) with zero cases of OHSS, compared to an expected 20-30% OHSS rate with hCG trigger. This protocol exploits kisspeptin's physiological induction of an endogenous LH surge rather than the supraphysiological, prolonged hCG stimulation that drives OHSS.
Hypothalamic Amenorrhea Studies
Jayasena et al. (2014) administered kisspeptin-54 (6.4 nmol/kg SC twice daily for 2 weeks) to women with hypothalamic amenorrhea (n=10). Treatment restored pulsatile LH secretion in 7 of 10 women and increased LH pulse frequency from 0.2 to 2.8 pulses per 8 hours. This demonstrated that the GnRH neuronal network remains responsive to kisspeptin stimulation even after prolonged quiescence, supporting kisspeptin as a potential therapeutic for functional hypothalamic amenorrhea.
Psychosexual Function Studies
Comninos et al. (2017) administered kisspeptin-54 (1 nmol/kg/h IV infusion for 75 minutes) to healthy heterosexual men (n=29) in a randomized, double-blind, placebo-controlled crossover fMRI study. Kisspeptin enhanced limbic brain activity in response to sexual and romantic images, specifically in the globus pallidus, posterior cingulate, and thalamus. Subjects also reported increased penile tumescence. This was the first demonstration that kisspeptin modulates human sexual brain processing.
Pharmacokinetic Profile
Kisspeptin-10 — Pharmacokinetic Curve
Intravenous injection, Subcutaneous injectionQuick Start
- Typical Dose
- 100mcg
- Route
- Intravenous injection, Subcutaneous injection
- Storage
- Refrigerate 2-8°C
Molecular Structure
- Formula
- C63H83N17O14
- Weight
- 1124.3 Da
- CAS
- 374675-21-5
- PubChem CID
- 25081104
- Exact Mass
- 1123.5531 Da
- LogP
- 10.2
- TPSA
- 224 Ų
- H-Bond Donors
- 5
- H-Bond Acceptors
- 11
- Rotatable Bonds
- 25
- Complexity
- 2080
Identifiers (SMILES, InChI)
InChI=1S/C65H73N9O9/c1-44(75)69-54(38-52-40-73(43-68-52)65(49-26-14-9-15-27-49,50-28-16-10-17-29-50)51-30-18-11-19-31-51)57(76)70-55(37-45-22-12-8-13-23-45)59(78)74-41-53(81-42-46-32-33-47-24-20-21-25-48(47)36-46)39-56(74)58(77)66-34-35-67-60(71-61(79)82-63(2,3)4)72-62(80)83-64(5,6)7/h8-33,36,40,43,53-56H,34-35,37-39,41-42H2,1-7H3,(H,66,77)(H,69,75)(H,70,76)(H2,67,71,72,79,80)/t53-,54-,55-,56-/m1/s1
MZBHONSBVVFVGT-FQFJSIKISA-NResearch Indications
Hormonal
Potent stimulator of LH and testosterone secretion in men via GnRH pathway. Increases LH pulse frequency and size. Multiple human clinical studies (PMID: 21632807, PMC3232613).
Under clinical investigation for restoring hormonal secretion in hypothalamic amenorrhea. Human clinical trials ongoing.
Investigated as a safer alternative to hCG for triggering oocyte maturation in assisted reproduction, reducing OHSS risk. Clinical trials in progress.
Metabolic
Proposed therapeutic target for metabolic-reproductive dysfunction in obesity and diabetes. Emerging preclinical and early clinical data (PMC11006622).
Under investigation for polycystic ovary syndrome-related reproductive dysfunction. Preclinical evidence with early human studies.
Research Protocols
subcutaneous Injection
Intravenous injection, Subcutaneous injection
Interactions
Peptide Interactions
Kisspeptin, neurokinin B, and dynorphin A are co-expressed in KNDy neurons of the arcuate nucleus, forming the GnRH pulse generator. Dynorphin acts as the inhibitory brake (via kappa-opioid receptors) while kisspeptin is the stimulatory output to GnRH neurons (via KISS1R/GPR54). This reciprocal NKB-stimulatory/Dyn-inhibitory mechanism generates rhythmic pulsatile GnRH secretion essential for mammalian reproduction (Navarro et al., 2009; Goodman et al., 2007).
Kisspeptin is the most potent known activator of GnRH neurons, binding KISS1R (GPR54) to stimulate GnRH release into the portal circulation. Kisspeptin-54 can trigger an endogenous LH surge comparable to GnRH agonist triggers in IVF while virtually eliminating OHSS risk (Abbara et al., 2015). Kisspeptin represents the upstream physiological activator of the GnRH-gonadotropin axis.
Comninos et al. (2017) showed that kisspeptin enhances limbic processing of sexual stimuli. Given that oxytocin modulates social bonding and sexual arousal through overlapping limbic circuits, researchers have proposed investigating combined kisspeptin-oxytocin paradigms for psychosexual disorder...
Kisspeptin's ability to trigger an endogenous LH surge makes it a potential replacement for GnRH agonist triggers in IVF. Abbara et al. (2015) demonstrated that kisspeptin-54 trigger produced comparable oocyte maturation to GnRH agonist trigger while virtually eliminating OHSS risk. Sequential ki...
What to Expect
What to Expect
Rapid onset expected; half-life of ~28 minutes indicates fast-acting pharmacokinetics
Treatment restored pulsatile LH secretion in 7 of 10 women and increased LH pulse frequency from 0.2 to 2.8 pulses per 8 hours.
Due to short half-life (~28 minutes), effects are expected per-dose; consistent daily administration maintains therapeutic levels
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Human clinical trials conducted
- Well-established safety profile
- Extensive peer-reviewed research base
- Oral administration available
Caution
- Short half-life may require frequent dosing
Red flags
- Significant side effect risk noted
Frequently Asked Questions
References (11)
- [10]
- [11]
- [6]Cho et al *Int Int. J. Oncol. (2009)
- [1]Seminara et al *N N. Engl. J. Med. (2003)
- [3]
- [4]Kotani et al *J J. Biol. Chem. (2001)
- [5]Lee et al *Biochem Biochem. Biophys. Res. Commun. (2005)
- [7]
- [12]
- [13]
- [9]Mead et al *Cardiovasc Cardiovasc. Res. (2007)
KGF (Keratinocyte Growth Factor)
KGF (FGF-7) is a 163-amino acid growth factor that specifically targets keratinocytes via the FGFR2-IIIb receptor, with clinical applications in mucositis treatment, wound healing, and hair follicle biology.
Kisspeptin-54
Kisspeptin-54 (metastin) is the full-length bioactive fragment of the KISS1 gene product (amino acids 68-121), a 54-amino acid peptide that activates KISS1R (GPR54) to regulate GnRH pulsatility, LH/FSH release, and reproductive function. It has a longer half-life than kisspeptin-10 and is being developed as an IVF trigger to prevent ovarian hyperstimulation syndrome.